Clinical Application Of Dexmedetomidine In Postoperative Delirium Of Critically Ill Patients

Postoperative delirium is an extremely common postoperative complication in patients undergoing surgery,which seriously affects the recovery of patients.It not only increases the incidence of various postoperative complications and decreases the long-term quality of life,but also prolongs the length of hospital stay and aggravates the economic burden of patients.Patients in the intensive care unit is also in great danger of postoperative delirium.Patients with critical illness are prone to delirium due to severe pathophysiological changes and changes in sleep structure.Therefore,timely identification and treatment of postoperative delirium is of great significance for reducing the incidence of various complications in hospitalized patients,reducing the cost of treatment and improving the prognosis of patients,which should be highly valued by clinicians.Dexmedetomidine is a new type of highly selective 2 adrenergic receptor agonist.Since 1999,when it was approved by the U.S Food and Drug Administration for the sedation of ICU patients with mechanical ventilation,it has shown a wide range of clinical advantages in many fields,andcatched the attention of scholars and clinicians.In recent years,it has been found that dexmedetomidine has great potential in the prevention of postoperative delirium,which has become a hot spot in clinical research.It was found in previous clinical practice that perioperative loading dose of dexmedetomidine following continuous infusion at a certain speed should have an effect of reducing the incidence of postoperative delirium and complication,the serious degree of delirium,length of stay in hospital,hospitalization cost and mortality.Other interventions including multi-component non-pharmacological intervention and the use of other antidelirium medications can enhance the role of dexmedetomidine in postoperative delirium management.It should be a superior and clinical feasible program which is centered on dexmedetomidine and combined with other interventions that will significantly improve the outcomes of postoperative delirium patients.